Affymetrix Releases Data From Validated SNP Database for Design of Custom Genotyping Arrays
Validated SNPs From 1000 Genomes Project and Custom Axiom Arrays Will Enable the Next Wave of Genotyping Studies
Validated SNPs From 1000 Genomes Project and Custom Axiom Arrays Will Enable the Next Wave of Genotyping Studies
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) today announced that it has released an unparalleled data set based on extensive validation of novel SNPs from the 1000 Genomes Project. This data will give researchers access to more rare mutations for genome-wide association studies and will enable the rapid design of custom arrays for a variety of applications, including the validation of sequencing results.
“The wealth of information that accompanied the genotype calls was paramount to the successful design of our array.”
In an ongoing effort to screen novel, newly discovered SNPs, Affymetrix has used the Axiom™ Genotyping Solution to screen millions of SNPs across multiple populations. The release of this data set—comprising approximately 500,000 SNPs from the 1000 Genomes Project that have been genotyped across the 270 HapMap samples—demonstrates the comprehensiveness of Affymetrix’ larger, highly curated database, which contains genotype calls and other useful annotations across millions of SNPs.
A team of researchers at the University of California, San Francisco (UCSF) and Kaiser Permanente’s Division of Research have used the initial data set to design a custom array as part of a 100,000-sample genotyping study for Kaiser Permanente’s Research Program on Genes, Environment, and Health (RPGEH).
“Without this data set, we could not have easily achieved the objectives of our initial custom array design, which included genomic coverage, inclusion of SNPs of interest, and coverage of genes thought to be highly relevant in our study,” said Dr. Neil Risch, Director of the Institute for Human Genetics at UCSF. “The wealth of information that accompanied the genotype calls was paramount to the successful design of our array.”
By combining SNPs from this data set with Affymetrix’ Axiom Custom Genotyping Arrays, which enable researchers to customize up to 2.6 million SNPs on a single array plate, the next wave of genome-wide association studies can now be realized. The comprehensive information contained in the data set can also be used in conjunction with a variety of imputation techniques that are gaining in adoption.
“This groundbreaking work has taken raw data from discovery projects and translated it into the first usable format,” said Kevin King, President and CEO of Affymetrix. “This will enable scientists to effectively use the 1000 Genomes Project SNP data and a host of other validated SNPs and annotations from different sources. By combining this data with our Axiom Custom Genotyping Arrays, researchers in need of custom arrays are no longer constrained by information or technology limitations.”
To learn more, please visit our website.
About Affymetrix
Affymetrix technology is used by the world’s top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 21,000 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit www.affymetrix.com.
UCSF disclaimer
The information stated above was prepared by Affymetrix, Inc. and reflects solely the opinion of Affymetrix, Inc. Nothing in this statement shall be construed to imply any support or endorsement of Affymetrix, Inc., or any of its products, by The Regents of the University of California, its officers, agents and employees.
Forward-looking statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2009, and other SEC reports for subsequent quarterly periods.
NOTE: Affymetrix, the Affymetrix logo, and Axiom are trademarks or registered trademarks of Affymetrix Inc.
